Current Status and Management of Chronic Myeloid Leukemia in the Gulf Region: Survey Results and Expert Opinion.

Giuseppe Saglio, Mohamed Yassin,Ahmad Alhuraiji,Amar Lal,Arif Alam,Faraz Khan, Fatima Khadada,Hani Osman, Islam Elkonaissi,Mahmoud Marashi,Mohamed Abuhaleeqa,Murtadha Al-Khabori,Ramesh Pandita,Salam Al-Kindi, Shakir Bahzad, Dayane Daou, Yasmin Al Qudah

Cancers(2024)

Cited 0|Views4
No score
Abstract
Studies on chronic myeloid leukemia (CML) in the Gulf region are scarce, consisting of a survey and expert meeting that included 15 experts in 2023 which discussed CML diagnosis, testing, treatment objectives, toxicities, and discontinuation in the Gulf region. Most patients were reported to be in first-line therapy, and the most common treatments were imatinib/imatinib generic in first-line and dasatinib in second- and third-lines. Mutation analysis was not reported to be routinely performed at the time of diagnosis but rather in case of progression to accelerated/blast phase or any sign of loss of response. While all participants were aware that BCR-ABL should be monitored every three months during the first year of treatment, 10% reported monitoring BCR-ABL every six months in practice due to test cost and lab capability. The most important first-line therapy objective was "achievement of major molecular response" (MMR) in younger patients and "overall survival" in older ones. The most important treatment objectives were "MMR" and "early molecular response followed by prolongation of overall survival" in the short term and "treatment-free remission" in the long term. The current practices in CML in the Gulf region appear to be similar to global figures.
More
Translated text
Key words
chronic myeloid leukemia,Gulf Council countries,survey,expert opinion
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined